Afatinib, a covalent inhibitor of the epidermal growth factor receptors (EGFR), was approved by the FDA for the treatment of EGFR-driven non-small cell lung carcinoma (NSCLC) in 2013 (Figure 1A). Here, EGFR is linked to non-small cell lung carcinoma.